RETEVMO

Product NDC
0002-5562
11-digit product format
000025562
Labeler code
0002
Product ID
0002-5562_94e137ac-9f6b-4904-8999-3e55603a2407
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
selpercatinib
Dosage form
TABLET, COATED
Route
ORAL
Labeler
Eli Lilly and Company
Application
NDA218160
Marketing category
NDA
Marketing start
2024-04-10
Substance
SELPERCATINIB
Active strength
160 mg/1
Pharmacologic classes
Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N218160-001RETEVMOSELPERCATINIB40MGTABLET / ORALRLD2024-04-10
N218160-002RETEVMOSELPERCATINIB80MGTABLET / ORALRLD2024-04-10
N218160-003RETEVMOSELPERCATINIB120MGTABLET / ORALRLD2024-04-10
N218160-004RETEVMOSELPERCATINIB160MGTABLET / ORALRLD, RS2024-04-10

Orange Book patents#

Application-product, Patent, Expiration table
Application-productPatentExpirationUse codeCoverage / statusSubmission date
N218160-001101129422037-10-10Drug substance, Drug product2024-05-09
N218160-001101371242037-10-10U-34502024-05-09
N218160-001101371242037-10-10U-39492024-05-09
N218160-001101371242037-10-10U-39502024-05-09
N218160-001101371242037-10-10U-39512024-05-09
N218160-001101728512037-10-10U-34502024-05-09
N218160-001101728512037-10-10U-39492024-05-09
N218160-001101728512037-10-10U-39502024-05-09
N218160-001101728512037-10-10U-39512024-05-09
N218160-00110112942*PED2038-04-10Pediatric extension
N218160-00110137124*PED2038-04-10Pediatric extension
N218160-00110172851*PED2038-04-10Pediatric extension
N218160-001121382502038-10-10U-39492024-12-05
N218160-001121382502038-10-10U-34502024-12-05
N218160-001121382502038-10-10U-39502024-12-05
N218160-001121382502038-10-10U-39512024-12-05
N218160-00112138250*PED2039-04-10Pediatric extension
N218160-002101129422037-10-10Drug substance, Drug product2024-05-09
N218160-002101371242037-10-10U-39492024-05-09
N218160-002101371242037-10-10U-39512024-05-09
N218160-002101371242037-10-10U-39502024-05-09
N218160-002101371242037-10-10U-34502024-05-09
N218160-002101728512037-10-10U-34502024-05-09
N218160-002101728512037-10-10U-39492024-05-09
N218160-002101728512037-10-10U-39502024-05-09
N218160-002101728512037-10-10U-39512024-05-09
N218160-00210112942*PED2038-04-10Pediatric extension
N218160-00210137124*PED2038-04-10Pediatric extension
N218160-00210172851*PED2038-04-10Pediatric extension
N218160-002121382502038-10-10U-39492024-12-05
N218160-002121382502038-10-10U-39502024-12-05
N218160-002121382502038-10-10U-39512024-12-05
N218160-002121382502038-10-10U-34502024-12-05
N218160-00212138250*PED2039-04-10Pediatric extension
N218160-003101129422037-10-10Drug substance, Drug product2024-05-09
N218160-003101371242037-10-10U-34502024-05-09
N218160-003101371242037-10-10U-39492024-05-09
N218160-003101371242037-10-10U-39502024-05-09
N218160-003101371242037-10-10U-39512024-05-09
N218160-003101728512037-10-10U-34502024-05-09
N218160-003101728512037-10-10U-39492024-05-09
N218160-003101728512037-10-10U-39502024-05-09
N218160-003101728512037-10-10U-39512024-05-09
N218160-00310112942*PED2038-04-10Pediatric extension
N218160-00310137124*PED2038-04-10Pediatric extension
N218160-00310172851*PED2038-04-10Pediatric extension
N218160-003121382502038-10-10U-34502024-12-05
N218160-003121382502038-10-10U-39492024-12-05
N218160-003121382502038-10-10U-39502024-12-05
N218160-003121382502038-10-10U-39512024-12-05
N218160-00312138250*PED2039-04-10Pediatric extension
N218160-004101129422037-10-10Drug substance, Drug product2024-05-09
N218160-004101371242037-10-10U-39492024-05-09
N218160-004101371242037-10-10U-39512024-05-09
N218160-004101371242037-10-10U-39502024-05-09
N218160-004101371242037-10-10U-34502024-05-09
N218160-004101728512037-10-10U-34502024-05-09
N218160-004101728512037-10-10U-39492024-05-09
N218160-004101728512037-10-10U-39512024-05-09
N218160-004101728512037-10-10U-39502024-05-09
N218160-00410112942*PED2038-04-10Pediatric extension
N218160-00410137124*PED2038-04-10Pediatric extension
N218160-00410172851*PED2038-04-10Pediatric extension
N218160-004121382502038-10-10U-39492024-12-05
N218160-004121382502038-10-10U-39502024-12-05
N218160-004121382502038-10-10U-39512024-12-05
N218160-004121382502038-10-10U-34502024-12-05
N218160-00412138250*PED2039-04-10Pediatric extension

Orange Book exclusivity#

Application-product, Exclusivity code, Expiration table
Application-productExclusivity codeExpiration
N218160-001ODE*2027-05-08
N218160-001ODE*2027-05-08
N218160-001ODE*2027-05-08
N218160-001M-3112027-09-27
N218160-001M-3122027-09-27
N218160-001PED2027-11-08
N218160-001PED2027-11-08
N218160-001PED2027-11-08
N218160-001PED2028-03-27
N218160-001PED2028-03-27
N218160-001ODE*2029-09-21
N218160-001ODE*2029-09-21
N218160-001PED2030-03-21
N218160-001PED2030-03-21
N218160-001ODE*2031-05-29
N218160-001ODE*2031-05-29
N218160-001ODE*2031-05-29
N218160-001PED2031-11-29
N218160-001PED2031-11-29
N218160-001PED2031-11-29
N218160-002ODE*2027-05-08
N218160-002ODE*2027-05-08
N218160-002ODE*2027-05-08
N218160-002M-3112027-09-27
N218160-002M-3122027-09-27
N218160-002PED2027-11-08
N218160-002PED2027-11-08
N218160-002PED2027-11-08
N218160-002PED2028-03-27
N218160-002PED2028-03-27
N218160-002ODE*2029-09-21
N218160-002ODE*2029-09-21
N218160-002PED2030-03-21
N218160-002PED2030-03-21
N218160-002ODE*2031-05-29
N218160-002ODE*2031-05-29
N218160-002ODE*2031-05-29
N218160-002PED2031-11-29
N218160-002PED2031-11-29
N218160-002PED2031-11-29
N218160-003ODE*2027-05-08
N218160-003ODE*2027-05-08
N218160-003ODE*2027-05-08
N218160-003M-3112027-09-27
N218160-003M-3122027-09-27
N218160-003PED2027-11-08
N218160-003PED2027-11-08
N218160-003PED2027-11-08
N218160-003PED2028-03-27
N218160-003PED2028-03-27
N218160-003ODE*2029-09-21
N218160-003ODE*2029-09-21
N218160-003PED2030-03-21
N218160-003PED2030-03-21
N218160-003ODE*2031-05-29
N218160-003ODE*2031-05-29
N218160-003ODE*2031-05-29
N218160-003PED2031-11-29
N218160-003PED2031-11-29
N218160-003PED2031-11-29
N218160-004ODE*2027-05-08
N218160-004ODE*2027-05-08
N218160-004ODE*2027-05-08
N218160-004M-3112027-09-27
N218160-004M-3122027-09-27
N218160-004PED2027-11-08
N218160-004PED2027-11-08
N218160-004PED2027-11-08
N218160-004PED2028-03-27
N218160-004PED2028-03-27
N218160-004ODE*2029-09-21
N218160-004ODE*2029-09-21
N218160-004PED2030-03-21
N218160-004PED2030-03-21
N218160-004ODE*2031-05-29
N218160-004ODE*2031-05-29
N218160-004ODE*2031-05-29
N218160-004PED2031-11-29
N218160-004PED2031-11-29
N218160-004PED2031-11-29

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RETEVMOSELPERCATINIBEli Lilly and Company7fa848ba-a59c-4144-9f52-64d090f4d8282026-07-14Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Monitor ALT and AST prior to initiating RETEVMO, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue RETEVMO based on severity. ( 2.5 , 5.1 ) Interstitial Lung Disease (ILD)/Pneumonitis: Monitor for new or worsening pulmonary symptoms. Withhold, reduce the dose or permanently discontinue RETEVMO based on severity. ( 2.5 , 5.2 ) Hypertension: Do not initiate RETEVMO in patients with uncontrolled hypertension. Optimize blood pressure (BP) prior to initiating RETEVMO. Monitor BP after 1 week, at least monthly thereafter and as clinically indicated. Withhold, reduce the dose, or permanently discontinue RETEVMO based on severity. ( 2.5 , 5.3 ) QT Interval Prolongation: Monitor patients who are at significant risk of developing QTc prolongation. Assess QT interval, electrolytes and TSH at baseline and periodically during treatment. Monitor QT interval more frequently when RETEVMO is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and reduce the dose or permanently discontinue RETEVMO based on severity. ( 2.5 , 5.4 ) Hemorrhagic Events: Permanently discontinue RETEVMO in patients with severe or life-threatening hemorrhage. ( 2.5 , 5.5 ) Hypersensitivity: Withhold RETEVMO and initiate corticosteroids. Upon resolution, resume at a reduced dose and increase dose by 1 dose level each week until reaching the dose taken prior to onset of hypersensitivity. Continue steroids until patient reaches target dose and then taper. ( 2.5 , 5.6 ) Tumor Lysis Syndrome: Closely monitor patients at risk and treat as clinically indicated. ( 5.7 ) Risk of Impaired Wound Healing: Withhold RETEVMO for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of RETEVMO after resolution of wound healing complications has not been established. ( 5.8 ) Hypothyroidism: Monitor thyroid function before treatment with RETEVMO and periodically during treatment. Withhold until clinically stable or permanently discontinue based on severity. ( 5.9 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the possible risk to a fetus and to use effective ...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hepatotoxicity [see Warnings and Precautions ( 5.1 )] Interstitial Lung Disease / Pneumonitis [see Warnings and Precautions ( 5.2 )] Hypertension [see Warnings and Precautions ( 5.3 )] QT Interval Prolongation [see Warnings and Precautions ( 5.4 )] Hemorrhagic Events [see Warnings and Precautions ( 5.5 )] Hypersensitivity [see Warnings and Precautions ( 5.6 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.7 )] Risk of Impaired Wound Healing [see Warnings and Precautions ( 5.8 )] Hypothyroidism [see Warnings and Precautions ( 5.9 )] Slipped Capital Femoral Epiphysis/Slipped Upper Femoral Epiphysis in Adolescent Patients [see Warnings and Precautions ( 5.11 )] The most common adverse reactions (≥25%) include: Adult patients with solid tumors: musculoskeletal pain, edema, diarrhea, fatigue, dry mouth, hypertension, abdominal pain, rash, nausea, constipation, cough, headache, vomiting, dyspnea, and hemorrhage. ( 6 ) Pediatric patients with solid tumors : musculoskeletal pain, diarrhea, nausea, hemorrhage, pyrexia, abdominal pain, headache, vomiting, fatigue, cough, rash, coronavirus infection, upper respiratory tract infection, and edema. ( 6 ) The most common Grade 3 or 4 laboratory abnormalities (≥5%) include: Adult patients with solid tumors: decreased lymphocytes, increased alanine aminotransferase (ALT), decreased sodium, increased aspartate aminotransferase (AST), decreased calcium, and decreased phosphate. ( 6 ) Pediatric patients with solid tumors: decreased lymphocytes, decreased calcium, decreased hemoglobin, decreased neutrophils, increased alanine aminotransferase, decreased magnesium, and decreased potassium. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety population described in the WARNINGS and PRECAUTIONS and below reflects exposure to RETEVMO as a single agent administered at 160 mg orally twice daily evaluated...

adverse reactions table

Table 6: Adverse Reactions (≥20%) in Patients Who Received RETEVMO in LIBRETTO-001 Adverse ReactionRETEVMO (n = 857)Grades 1-4# (%)Grades 3-4 (%)1 Musculoskeletal pain includes back pain, arthralgia, pain in extremity, myalgia, musculoskeletal pain, neck pain, musculoskeletal chest pain, non-cardiac chest pain, bone pain, musculoskeletal stiffness, spinal pain. 2 Edema includes edema peripheral, face edema, periorbital edema, eye edema, eyelid edema, orbital edema, localized edema, lymphedema, scrotal edema, peripheral swelling, scrotal swelling, swelling, swelling face, eye swelling, generalized edema, genital edema, angioedema, penile edema, skin edema, testicular swelling, vulvovaginal swelling 3 Fatigue includes asthenia, malaise. 4 Diarrhea includes defecation urgency, frequent bowel movements, gastrointestinal hypermotility, anal incontinence. 5 Dry mouth includes mucosal dryness 6 Abdominal pain includes abdominal pain upper, abdominal pain lower, abdominal discomfort, abdominal tenderness, epigastric discomfort, gastrointestinal pain. 7 Vomiting includes regurgitation, retching. 8 Hypertension includes blood pressure increased 9 Rash includes skin exfoliation, rash erythematous, rash macular, rash maculopapular, rash morbilliform, rash papular, rash pruritic, butterfly rash, exfoliative rash, rash follicular, rash generalized, rash vesicular, dermatitis, urticaria, dermatitis allergic, rash pustular. 10 Cough includes productive cough, upper airway cough syndrome 11 Dyspnea includes dyspnea exertional, dyspnea at rest 12 Headache includes sinus headache, tension headache. 13 Dizziness includes vertigo, presyncope, dizziness postural. 14 Hemorrhage includes epistaxis, hematuria, hemoptysis, contusion, rectal hemorrhage, vaginal hemorrhage, ecchymosis, hematochezia, international normalized ratio increased, petechiae, traumatic hematoma, anal hemorrhage, blood blister, blood urine present, cerebral hemorrhage, hematocrit decreased, gastric hemorrhage, hemorrhage intracranial, hemorrhage subcutaneous, spontaneous hematoma, abdominal wall hematoma, angina bullosa hemorrhagica, arterial hemorrhage, coagulopathy, conjunctival hemorrhage, disseminated intravascular coagulation, diverticulum intestinal hemorrhagic, eye contusion, eye hematoma, eye hemorrhage, gastrointestinal hemorrhage, gingival bleeding, hematemesis, hemorrhagic stroke, hemothorax, hemo...

Additional Listing Data#

Finished product
Yes
Brand name base
RETEVMO
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
SELPERCATINIB160 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
UniiCEGM9YBNGD
Rxcui2370164, 2370170, 2370172, 2370174, 2679805, 2679808, 2679810, 2679812, 2679813, 2679814, 2679815, 2679816

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
481381ff-cc0d-406c-b479-0f9e6be2c48aProduct name120201001

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0002-5562-60RETEVMO60 in 1 BOTTLETABLET, COATED6022

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0002-5562-60EA - Each0002-556255a9e210-d9e2-408e-bc37-4006548aa92912024-08-12

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0002-5562RETEVMO (SELPERCATINIB) CAPSULE RETEVMO (SELPERCATINIB) TABLET, COATED [ELI LILLY AND COMPANY]18Current NDC, 1 package rows20250103_7fa848ba-a59c-4144-9f52-64d090f4d828.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
2679808Retevmo 120 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679812Retevmo 160 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2370170Retevmo 40 MG Oral CapsulePSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679814Retevmo 40 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2370174Retevmo 80 MG Oral CapsulePSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679816Retevmo 80 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679805selpercatinib 120 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679810selpercatinib 160 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2370164selpercatinib 40 MG Oral CapsulePSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679813selpercatinib 40 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2370172selpercatinib 80 MG Oral CapsulePSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679815selpercatinib 80 MG Oral TabletPSN7fa848ba-a59c-4144-9f52-64d090f4d82822
2679808selpercatinib 120 MG Oral Tablet [Retevmo]SBD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679812selpercatinib 160 MG Oral Tablet [Retevmo]SBD7fa848ba-a59c-4144-9f52-64d090f4d82822
2370170selpercatinib 40 MG Oral Capsule [Retevmo]SBD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679814selpercatinib 40 MG Oral Tablet [Retevmo]SBD7fa848ba-a59c-4144-9f52-64d090f4d82822
2370174selpercatinib 80 MG Oral Capsule [Retevmo]SBD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679816selpercatinib 80 MG Oral Tablet [Retevmo]SBD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679805selpercatinib 120 MG Oral TabletSCD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679810selpercatinib 160 MG Oral TabletSCD7fa848ba-a59c-4144-9f52-64d090f4d82822
2370164selpercatinib 40 MG Oral CapsuleSCD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679813selpercatinib 40 MG Oral TabletSCD7fa848ba-a59c-4144-9f52-64d090f4d82822
2370172selpercatinib 80 MG Oral CapsuleSCD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679815selpercatinib 80 MG Oral TabletSCD7fa848ba-a59c-4144-9f52-64d090f4d82822
2679808Retevmo 120 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679812Retevmo 160 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2370170Retevmo 40 MG Oral CapsuleSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679814Retevmo 40 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2370174Retevmo 80 MG Oral CapsuleSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679816Retevmo 80 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679805selpercatinib 120 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679810selpercatinib 160 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679813selpercatinib 40 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822
2679815selpercatinib 80 MG Oral TabletSY7fa848ba-a59c-4144-9f52-64d090f4d82822

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
0002-5562-600000255626060 TABLET, COATED in 1 BOTTLE (0002-5562-60) 2024-04-10NoNoCurrent